Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-932 in depressive episodes of bipolar I or II disorder
jRCT2061240082Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of ABBV-932 in bipolar I disorder and Bipolar II disorder (BP-II) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. Started Nov 2024; status: completed.
02
Drugs
ABBV-932
03
Conditions
bipolar I disorderBipolar II disorder (BP-II)
Beyond the preview
Go deeper on jRCT2061240082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240082.